兴齐眼药：硫酸阿托品滴眼液药品补充申请获批 完善产品矩阵

Core Viewpoint - Xingqi Eye Pharmaceutical has received approval from the National Medical Products Administration for the supplementary application of atropine sulfate eye drops, expanding its product specifications to include 0.02% and 0.04% concentrations, which are currently not available in the domestic market [1][2] Group 1: Product Development - The new product specifications of 0.02% (0.4ml: 0.08mg) and 0.04% (0.4ml: 0.16mg) will enhance the company's product matrix, addressing the unmet needs in myopia treatment for children and adolescents [1][2] - The company has a comprehensive product line that includes treatments for myopia progression, dry eye, infections, inflammation, and glaucoma, establishing a robust portfolio in ophthalmic medications [1] Group 2: Financial Performance - For the first three quarters of 2025, the company reported a revenue of 1.904 billion yuan, reflecting a year-on-year growth of 32.27%, driven by core products like atropine [2] - The approval of the new formulations is expected to further boost the company's sales performance and market presence in the ophthalmic sector [2] Group 3: Strategic Initiatives - The company aims to enhance product accessibility and patient experience through innovative drug pipelines, differentiated product strategies, and academic promotion in the field of myopia prevention [2] - Industry experts believe that the approval of the new formulations will facilitate continuous product iteration and better meet the treatment needs for myopia in young patients [2]